7 citations
,
November 2021 in “JAAD Case Reports” Mogamulizumab can cause hair loss and skin rashes.
54 citations
,
May 2019 in “Multiple Sclerosis and Related Disorders” Azathioprine can help with relapses and disability in NMOSD but has more side effects and needs more research.
30 citations
,
January 2024 in “Frontiers in Pharmacology” These migraine prevention drugs can cause side effects like constipation, hair loss, injection site reactions, fatigue, and sometimes unexpected issues like Raynaud's phenomenon and weight gain.
January 2024 in “Wiadomości Lekarskie” Using Decamethoxine and Blastomunil together speeds up wound healing.
40 citations
,
November 2017 in “International journal of nanomedicine” DA liposomes with chloramphenicol effectively target hair follicles and combat MRSA with minimal skin toxicity.
June 2016 in “Annals of the rheumatic diseases” Methotrexate is effective for treating rheumatoid arthritis but requires regular monitoring.
97 citations
,
December 2011 in “New England Journal of Medicine” The FDA did not approve certain drugs for prostate cancer prevention due to concerns about their effectiveness and potential risks.
5 citations
,
May 2024 in “Journal of Allergy and Clinical Immunology Global” Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.
November 2023 in “Clinical, Cosmetic and Investigational Dermatology” A man's rash caused by Finasteride improved after stopping the drug and starting new treatments.
9 citations
,
October 2015 in “Cutaneous and ocular toxicology” Vemurafenib can cause scalp issues but can be managed without changing the dose.
June 2025 in “Neurology India” Anti-SRP myopathy can be linked to systemic lupus erythematosus and may improve with specific treatment.
October 2025 in “Frontiers in Medicine” Ixekizumab has known and some unexpected side effects.
March 2010 in “Anti-inflammatory & anti-allergy agents in medicinal chemistry” Biologic agents can be effective for rheumatic diseases but have risks like infections and require careful monitoring and patient information.
1 citations
,
May 2022 in “European Journal of Dermatology” Longer treatment with vismodegib lowers relapse risk in basal cell carcinoma.
March 2022 in “Oncology Times” Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.
August 2018 in “Journal of The American Academy of Dermatology” Ozenoxacin 1% cream is an effective and safe treatment for impetigo in children and adults.
6 citations
,
October 2023 in “JAAD Case Reports” Risankizumab may help manage symptoms of dissecting cellulitis of the scalp.
25 citations
,
October 2015 in “Dermatology” Dapsone improved pustular psoriasis in patients who didn't respond to other treatments and is considered a well-tolerated option.
15 citations
,
January 2006 in “British Journal of Dermatology” A woman with skin eruptions and hair loss improved significantly with ointment treatment.
April 2025 in “Journal of Pharmaceutical Investigation” Low-dose rapamycin microdepots can help regrow hair by activating certain cell processes.
November 2025 in “The Journal of Dermatology” Nemolizumab improved both severe atopic dermatitis and alopecia areata in one patient.
2 citations
,
November 2004 in “Hospital pharmacy” Certain medications can cause serious side effects, so it's important to report them.
176 citations
,
June 2016 in “PLoS ONE” Nucleic acid polymers can enhance antiviral responses and improve treatment outcomes for chronic hepatitis B.
1 citations
,
August 2022 in “American Journal of Tropical Medicine and Hygiene” Scalp abscesses can occur after hair loss treatments and may be caused by Mycobacterium abscessus.
1 citations
,
January 2008 in “SKINmed Dermatology for the Clinician” Treatment with prednisolone and dapsone stopped new blisters and partially healed previous ones.
22 citations
,
October 2007 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” Combining isotretinoin and dapsone effectively treated a challenging scalp condition.
April 2016 in “Journal of Investigative Dermatology” MEK and BRAF inhibitors increase sebum production and accumulation, which could cause acne-like side effects.
April 2012 in “Journal of the American Academy of Dermatology” Clofazimine effectively treated ashy dermatosis in a patient.
22 citations
,
January 2012 in “Mediators of inflammation” Nonantibiotic macrolides show promise for treating various inflammatory skin conditions.
1 citations
,
July 2024 in “Journal of Investigative Dermatology” TAK-279 effectively reduces psoriasis symptoms and is safe.